TET2 and hematologic disorder: In addition to hematological malignancies, recently, increasing evidences demonstrate that TET2 is implicated in progression of solid tumors, including prostate cancer, gastric cancer, epithelial ovarian cancer, melanoma and breast cancer7,8,16–18.